Cancer Research
At MetroHealth, our oncologists are passionate about delivering high-quality, state-of-the-art care to cancer patients from Cuyahoga County and across Ohio. Every day, we offer health-restoring therapies that help our patients fight back against the cancer cells that make them sick. We continue to strive to learn more about the many cancers that impact members of our community.
To find out more about these studies, or to enroll in a study that might be right for you or your cancer, contact our oncology team at 216-77-TREAT.
Research Helps Us Fight Even More Effectively
Our oncologists participate in cancer research to learn more about how cancer cells form and how they can be treated. This research helps people with cancer access new and cutting-edge therapies that might not be available elsewhere.
These are some of the cancer research studies available at MetroHealth right now:
| Study Name | Disease Site/Cancer Type | Stage |
|---|---|---|
| MetroHealth Cancer Center Tissue Repository (MHCC-TR) | All solid tumors | Nontherapeutic |
| A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation (A071102) | Brain | Adjuvant |
| A Physical Activity Intervention to Reduce Functional Health Disparities among Older Breast Cancer Survivors (Case 2116) | Breast | Nontherapeutic |
| Attitudes, Beliefs, and Preferences of Older Breast Cancer Survivors Towards Physical Activity (Case 5115) | Breast | Nontherapeutic |
| A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (E1Z11) | Breast | Nontherapeutic |
| HER2+GEN: An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive Metastatic Breast Cancer (ML28257) | Breast | Metastatic, nontherapeutic |
| A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (NRG-BR002) | Breast | Metastatic |
| A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003) | Breast | Adjuvant |
| A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT (NSABP-B-51) | Breast | Adjuvant |
| A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (NSABP-B-55) | Breast | Adjuvant |
| A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor: Positive and HER/neu Negative Breast Cancer (S1207) | Breast | Adjuvant |
| Quantification of Functional Cognitive Abilities in Breast and Colorectal Cancer Patients Receiving Adjuvant Chemotherapy: A Feasibility Study | Breast | Adjuvant, nontherapeutic |
| Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas (EA2142) | GI: neuroendocrine | Metastatic |
| Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study (A021302) | GI: stomach | Neoadjuvant PET scan |
| Quantification of Functional Cognitive Abilities in Breast and Colorectal Cancer Patients Receiving Adjuvant Chemotherapy: A Feasibility Study | GI: colon | Adjuvant, nontherapeutic |
| Ohio Colorectal Cancer Prevention Initiative: Universal Screening For Lynch Syndrome (OSU-20120CO123) | GI: colon | Nontherapeutic, all stages |
| A Pilot Study to Determine the Feasibility of a Low Glycemic Load Diet in Patients with Stage I-III Colon Cancer (Dietary Intervention in Colorectal Cancer Survivors) | GI: colon | Nontherapeutic |
| A Randomized Phase II Study of Irinotecan and Cetuximab (IMC-1121B) in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy (E7208) | GI: colorectal, K-RAS WT | Second line metastatic |
| A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (R0848) | GI: pancreatic | Adjuvant |
| A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Pacliaxel as Therapy for Resectable Pancreatic Adenocarcinoma (S1505) | GI: pancreatic | Neoadjuvant |
| A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection (N1048) | GI: rectal | Neoadjuvant, locally advanced |
| Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone, and Prednisone for Castration Resistant Metastatic Prostate Cancer (A031201) | GU: prostate | First line metastatic |
| Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (S1216) | GU: prostate | First line metastatic |
| Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy (E2810) | GU: renal cell | Adjuvant, metastatic |
| EVERST: EVErolimus for Renal Cancer, A Phase III Study (S0931) | GU: renal cell | Metastatic |
| A Random Phase II Study of Co-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer (S1314) | GU: bladder | Neoadjuvant |
| PAMMPET: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC# 749005], Savolitinib [NSC# 785348], and Sunitinib [NSC# 736511]) in Metastatic Papilllary Renal Carcinoma (S1500) | GU: renal | Metastatic |
| A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma (EA8141) | GU: upper tract | Neoadjuvant |
| Acquisition of Human Gynecologic Cancer Specimens and Serum to Study the Causes, Diagnosis, Prevention, and Treatment of Gynecologic Cancers (CASE-9812) | GYN | Nontherapeutic |
| Quantification of Functional Cognitive Abilities in Breast, Colorectal and Endometrial Cancer Patients Receiving Adjuvant Chemotherapy: A Feasibility Study | GYN: endometrial | Adjuvant, nontherapeutic |
| Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemotherapy in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy (GOG-0263) | GYN: cervical | Adjuvant |
| THE OUTBACK TRIAL: A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone (GOG-0274) | GYN: cervical | Locally advanced, adjuvant |
| A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube, and Peritoneal Primary Cancer (GOG-0213) | GYN: ovarian | 2nd line ovarian |
| A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer (JAVELIN OVARIAN) | GYN: ovarian | First line metastatic |
| A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) (NRG-GY005) | GYN: ovarian | Recurrence |
| A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer (NRG-GY006) | GYN: ovarian | Newly diagnosed, bulky |
| A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY004) | GYN: ovarian | Recurrence |
| A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects (CA184-201) | GYN: ovarian | Metastatic |
| Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) (EA3132) | Head and neck | Adjuvant |
| A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cituximab for Locally-Advanced Resected Head and Neck Cancer (R0920) | Head and neck | Adjuvant |
| Randomized, Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel And Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (R1216) | Head and neck | Adjuvant |
| The National Myelodysplastic Syndromes (MDS) Study (NHLBI-MDS) | Leukemia | Nontherapeutic |
| A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) (E1912) | Leukemia: CLL | First line |
| ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (A151216) | Lung | Adjuvant |
| ANVIL: Adjuvant Nivolumab in Resected Lung Cancer--A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (EA5142) | Lung | Adjuvant |
| Randomized Phase II Trial of Concurrent Chemoradiatiotherapy +/- Metformin HCL in Locally Advanced NSCLC (NRG-LU001) | Lung | First line |
| Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (S1400) | Lung | First-line metastatic |
| A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (E4512) | Lung: ALK mutated | Adjuvant |
| Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer (A081105) | Lung: EGFR mutated | Adjuvant |
| A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies (CHECKMATE 370) | Lung: squamous and non-squamous | Metastatic |
| A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs. Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer who Received 4 Months of Nivolumab at 3mg/kg or 240mg Every 2 Weeks (CHECKMATE 384) | Lung: squamous and non-squamous | Metastatic |
| Phase II Study of Dose-Adjuvested EPOCH +/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma (9177) | Lymphoma: Burkitt | First line |
| Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients w/ Newly Diagnosed Diffuse Large B Cell Lymphoma (E1412) | Lymphoma: DLCL | First line, metastatic |
| MAGNIFY: A Phase IIIB Randomized Study of Lenalidomide (CC-5103) plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma | Lymphoma: low grade | Second line |
| Intergroup Randomized PH II Four Arm Study In Patients >/= 60 with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A=Rituximab + Bendamustine Followed by Rituximab Consolidation (RB->R); Arm B= Rituximab+ Bendamustine + Bortezomib Followed by Rituximab Consolidation (RBV->R); Arm C= Rituximab + Bendamustine Followed by Lenalidomide + Rituximab Consolidation (RB->LR), or Arm D= Rituximab + Bendamustine + Bortezomib Followed by Lenalidomide and Rituximab Consolidation (RBV->LR) (E1411) | Lymphoma: mantle cell | First line, metastatic |
| A Randomized Phase III Trial of Debrafenib + Tramentinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Tranetinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma (EA6134) | Melanoma: BRAF+ | First line metastatic |
| Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Vs. Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (EA6141) | Melanoma: BRAF+/- | First line metastatic |
| A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma (S1404) | Melanoma: BRAF+/- | Adjuvant |
| A Randomized Phase II Trial of Intermittent vs. Continuous Dosing of Dabrafenib (NSC - 763760) and Trametinib (NSC - 763093) in BRAF V600E/K Mutant Melanoma (S1320) | Melanoma: BRAF+ | First line metastatic |
| ENDURANCE: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (E1A11) | Myeloma | First line |
| Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple Myeloma (E3A06) | Myeloma | First line |
| Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (Preamble - CA204008) | Myeloma | Nontherapeutic |
